Lang Ho Lee

Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

Niladri Roy Chowdhury, N. R. Chowdhury, E. L. Potter, 2021, Journal for ImmunoTherapy of Cancer.

Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms

P. Libby, Amitabh Sharma, A. Muscoloni, 2022, Circulation research.

Systems Approach to Discovery of Therapeutic Targets for Vein Graft Disease

Daniel G. Anderson, P. Libby, Amitabh Sharma, 2021, Circulation.

PPARα Pivotally Regulates Metabolism, Activation, and Heterogeneity of Macrophages and Lesion Development

Daniel G. Anderson, P. Libby, Amitabh Sharma, 2021 .

First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Rα, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors

D. McNeel, R. Leidner, R. Wesolowski, 2023, Journal for ImmunoTherapy of Cancer.